Praziquantel

Praziquantel Impurities

Praziquantel impurities include process-related compounds, synthetic intermediates, and degradation products that may arise during synthesis, formulation, or storage. As an anthelmintic agent used to treat schistosomiasis and other parasitic infections, impurity profiling is essential to ensure product safety, therapeutic efficacy, and regulatory compliance. All impurity compounds are structurally characterized and qualified under ICH guidelines for toxicological evaluation and analytical validation.

Praziquantel EP Impurities

Pharmacopeial and non-pharmacopeial Praziquantel impurity compounds are available in compliance with European Pharmacopoeia (EP) specifications. These standards support analytical method development, impurity profiling, and stability testing. EP traceable materials are supplied with validated analytical data including purity, structural confirmation, and spectral characterization.

Praziquantel Related Compounds

Structurally related compounds and synthetic analogs associated with Praziquantel are included for use in impurity identification, toxicological qualification, and regulatory submission. These materials are thoroughly characterized and conform to international standards. Related compounds are used in forced degradation studies, genotoxicity assessments, and impurity threshold evaluations.

Praziquantel Impurity Reference Standards

Praziquantel impurity reference standards are provided with validated analytical data including purity, NMR, and MS. These standards are used in pharmaceutical research, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request and are routinely re-tested to ensure consistency and reliability.